TY - JOUR
T1 - Splenic metabolic activity predicts risk of future cardiovascular events
T2 - Demonstration of a cardiosplenic axis in humans
AU - Emami, Hamed
AU - Singh, Parmanand
AU - Macnabb, Megan
AU - Vucic, Esad
AU - Lavender, Zachary
AU - Rudd, James H.F.
AU - Fayad, Zahi A.
AU - Lehrer-Graiwer, Joshua
AU - Korsgren, Magnus
AU - Figueroa, Amparo L.
AU - Fredrickson, Jill
AU - Rubin, Barry
AU - Hoffmann, Udo
AU - Truong, Quynh A.
AU - Min, James K.
AU - Baruch, Amos
AU - Nasir, Khurram
AU - Nahrendorf, Matthias
AU - Tawakol, Ahmed
N1 - Funding Information:
Funding for the first study (ACS Study) was provided by Genentech, Inc., and BioInvent International AB. No funding from any source was provided for the second study (Clinical Outcomes Study). Dr. Lehrer-Graiwer is an employee of and owns stock in Global Blood Therapeutics. At the time this study was conducted, Dr. Korsgren was employed by BioInvent International AB, Sweden. Dr. Fredrickson is an employee of and a shareholder in Genentech/Roche. Dr. Baruch is an employee of Genentech/Roche. Dr. Tawakol has received grant support from Genentech . All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Emami and Singh are joint first authors. George Beller, MD, has served as Guest Editor for this paper.
Publisher Copyright:
© 2015 American College of Cardiology Foundation.
Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Objectives This study sought to determine whether splenic activation after acute coronary syndrome (ACS) is linked to leukocyte proinflammatory remodeling and whether splenic activity independently predicts the risk of cardiovascular disease (CVD) events. Background Pre-clinical data suggest the existence of a cardiosplenic axis, wherein activation of hematopoietic tissues (notably in the spleen) results in liberation of proinflammatory leukocytes and accelerated atherosclerotic inflammation. However, it is presently unknown whether a cardiosplenic axis exists in humans and whether splenic activation relates to CVD risk. Methods 18F-fluorodeoxyglucose (18FDG)-positron emission tomography (PET) imaging was performed in 508 individuals across 2 studies. In the first study, we performed FDG-PET imaging in 22 patients with recent ACS and 22 control subjects. FDG uptake was measured in spleen and arterial wall, whereas proinflammatory gene expression of circulating leukocytes was assessed by quantitative real-time polymerase chain reaction. In a second study, we examined the relationship between splenic tissue FDG uptake with subsequent CVD events during follow-up (median 4 years) in 464 patients who previously had undergone FDG-PET imaging. Results Splenic activity increased after ACS and was significantly associated with multiple indices of inflammation: 1) up-regulated gene expression of proinflammatory leukocytes; 2) increased C-reactive protein; and 3) increased arterial wall inflammation (FDG uptake). Moreover, in the second study, splenic activity (greater than or equal to the median) was associated with an increased risk of CVD events (hazard ratio [HR]: 3.3; 95% confidence interval [CI]: 1.5 to 7.3; p = 0.003), which remained significant after adjustment for CVD risk factors (HR: 2.26; 95% CI: 1.01 to 5.06; p = 0.04) and for arterial FDG uptake (HR: 2.68; 95% CI: 1.5 to 7.4; p = 0.02). Conclusions Our findings demonstrate increased splenic metabolic activity after ACS and its association with proinflammatory remodeling of circulating leukocytes. Moreover, we observed that metabolic activity of the spleen independently predicted risk of subsequent CVD events. Collectively, these findings provide evidence of a cardiosplenic axis in humans similar to that shown in pre-clinical studies.
AB - Objectives This study sought to determine whether splenic activation after acute coronary syndrome (ACS) is linked to leukocyte proinflammatory remodeling and whether splenic activity independently predicts the risk of cardiovascular disease (CVD) events. Background Pre-clinical data suggest the existence of a cardiosplenic axis, wherein activation of hematopoietic tissues (notably in the spleen) results in liberation of proinflammatory leukocytes and accelerated atherosclerotic inflammation. However, it is presently unknown whether a cardiosplenic axis exists in humans and whether splenic activation relates to CVD risk. Methods 18F-fluorodeoxyglucose (18FDG)-positron emission tomography (PET) imaging was performed in 508 individuals across 2 studies. In the first study, we performed FDG-PET imaging in 22 patients with recent ACS and 22 control subjects. FDG uptake was measured in spleen and arterial wall, whereas proinflammatory gene expression of circulating leukocytes was assessed by quantitative real-time polymerase chain reaction. In a second study, we examined the relationship between splenic tissue FDG uptake with subsequent CVD events during follow-up (median 4 years) in 464 patients who previously had undergone FDG-PET imaging. Results Splenic activity increased after ACS and was significantly associated with multiple indices of inflammation: 1) up-regulated gene expression of proinflammatory leukocytes; 2) increased C-reactive protein; and 3) increased arterial wall inflammation (FDG uptake). Moreover, in the second study, splenic activity (greater than or equal to the median) was associated with an increased risk of CVD events (hazard ratio [HR]: 3.3; 95% confidence interval [CI]: 1.5 to 7.3; p = 0.003), which remained significant after adjustment for CVD risk factors (HR: 2.26; 95% CI: 1.01 to 5.06; p = 0.04) and for arterial FDG uptake (HR: 2.68; 95% CI: 1.5 to 7.4; p = 0.02). Conclusions Our findings demonstrate increased splenic metabolic activity after ACS and its association with proinflammatory remodeling of circulating leukocytes. Moreover, we observed that metabolic activity of the spleen independently predicted risk of subsequent CVD events. Collectively, these findings provide evidence of a cardiosplenic axis in humans similar to that shown in pre-clinical studies.
KW - FDG
KW - acute coronary syndrome
KW - atherosclerosis
KW - events
KW - inflammation
KW - spleen
UR - http://www.scopus.com/inward/record.url?scp=84923108209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923108209&partnerID=8YFLogxK
U2 - 10.1016/j.jcmg.2014.10.009
DO - 10.1016/j.jcmg.2014.10.009
M3 - Article
C2 - 25577441
AN - SCOPUS:84923108209
SN - 1936-878X
VL - 8
SP - 121
EP - 130
JO - JACC: Cardiovascular Imaging
JF - JACC: Cardiovascular Imaging
IS - 2
ER -